Clinical Trial Update: The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluated the effects of the GLP-1 analogue exenatide on Type 2 diabetes in the CNS and heart during hyperglycemia, assessed by PET.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: University of Aarhus | Conditions: Type 2 Diabetes | Phase 2, Phase 3 | Status: COMPLETED